VXRT News and Press, Vaxart Inc. From 11/08/22

Vaxart, Inc. (VXRT) Q3 2022 Earnings Conference Call November 8, 2022, 04:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chie...

Vaxart press release ( NASDAQ: VXRT ): Q3 GAAP EPS of -$0.23 beats by $0.01 . Vaxart ended the third quarter with cash, cash equivalents and available-for-sale debt securities of $114.8 million, compared to $131.5 million as of June 30, 2022. The de...

Growing body of clinical evidence supports transformational potential of Vaxart’s oral vaccine platform Clinical trial programs on track for reporting key data milestones Ended third quarter with $114.8 million in cash, cash equivalents and marketable securities ...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market c...

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in...

Just because a stock is down substantially doesn't mean it's worth investing in at its current levels. Many companies will rebound from the ongoing downturn as the economy improves, but in all likelihood, many others will continue to struggle. Corporations in the latter category are best av...

Summary Vaxart's stock briefly traded >$15 in 2020 when it was thought the company's oral COVID vaccine had been selected for Operation Warp Speed. That was not the case, but interest in the oral vaccine was sufficient to make its stock price volatile and rise >$10 twice in ...

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be presenting vi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biotechnology firm Vaxart (NASDAQ: VXRT ) traded all over the map on Thursday as the company released encouraging top-line data for the first of a two-part clinical study of its oral coronavirus vaccine. ...

Vaxart ( NASDAQ: VXRT ) said its Wuhan S-only oral pill COVID-19 vaccine VXA-CoV2-1.1-S. met the main safety and secondary immunogenicity goals in the first part of a planned two-part phase 2 trial. Part 1 of the study enrolled 66 healthy adults, including people wh...